Reaction

Mean Cell Haemoglobin Increased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,638 reports · 48 co-occurring drugs

As of the last recalculation, Mean Cell Haemoglobin Increased appears in 1,638 FAERS reports alongside 48 co-occurring drug terms. The strongest observed disproportionality signal is DIMENHYDRINATE (PRR 52.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Dimenhydrinate	43	52.6	52.8
Niraparib	65	38.7	38.8
Ribociclib	86	36.5	36.6
Alemtuzumab	52	35.3	35.3
Drs. Clotrimazole	27	30.2	30.2
Family Wellness Clotrimazole	27	30.2	30.2
Clotrimazole Topical	27	30.2	30.2
Desloratadine	25	30.1	30.1
Letrozole	131	29.3	29.3
Clotrimazole	27	28.4	28.4
Fulvestrant	70	28.1	28.1
Letrozole Tablets	100	28.1	28.1
Cimetidine	20	26.7	26.8
Palbociclib	150	21.9	21.9
Anastrozole Tablets	34	20.5	20.6
Ketoconazole	25	18.6	18.6
Eculizumab	75	18.3	18.4
Febuxostat Tablets 40 Mg	14	17.6	17.7
Febuxostat Tablets 80 Mg	14	17.6	17.7
Rucaparib	12	17.4	17.4
Anastrozole	44	15.6	15.6
Clozapine	140	15.4	15.4
Methylprednisolone Sodium Succinate	54	15.3	15.3
Ravulizumab	15	14.2	14.2
Ado-Trastuzumab Emtansine	9	13.6	13.6
Zoledronic Acid	39	12.6	12.6
Rosuvastatin Calcium	24	11.0	11.0
Febuxostat	14	10.7	10.7
Goserelin	11	10.5	10.5
Insulin Glulisine	7	8.8	8.8
Exemestane	14	8.4	8.4
Cladribine	6	8.0	8.0
Dutasteride	5	7.8	7.8
Tafamidis	7	7.6	7.6
Avapritinib	7	7.4	7.4
Dapagliflozin	17	6.9	6.9
Pazopanib Hydrochloride	14	6.6	6.6
Pertuzumab	14	6.6	6.6
Bevacizumab	61	6.5	6.5
Asfotase Alfa	5	6.4	6.4
Cannabidiol	11	6.0	6.0
Alpelisib	4	5.8	5.8
Tolvaptan	6	5.3	5.3
Belimumab	13	5.3	5.3
Fingolimod Hcl	35	5.2	5.2
Deferasirox	10	4.8	4.8
Olaparib	6	3.7	3.7
Dalfampridine	18	3.2	3.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.